Home › Glioblastoma › Illinois
Glioblastoma clinical trials in Illinois
16 studies for Glioblastoma are looking for participants at sites in Illinois.
Cities in Illinois
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Rush University Medical Center, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07195591Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- University of Chicago Comprehensive Cancer Center, Chicago
- University of Chicago Medicine-Orland Park, Orland Park
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT05432804A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- Northwestern Medicine, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07464925A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
- Northwestern Univerity, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT05303467A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Northwestern Memorial Hospital, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05765812Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06860594Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Northwestern Memorial Hospital, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06810544SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
- Alton Memorial Hospital, Alton
- Decatur Memorial Hospital, Decatur
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07452458Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
- Northwestern University, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06410248Targeted Pediatric High-Grade Glioma Therapy
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Northwestern University, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05879250Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.